Top

Published in:

Open Access 01-12-2008 | Review Paper

A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment

Authors: Frédéric Dayan, Nathalie M. Mazure, M. Christiane Brahimi-Horn, Jacques Pouysségur

Published in: Cancer Microenvironment | Issue 1/2008

Abstract

The hypoxia-inducible factor is the key protein responsible for the cellular adaptation to low oxygen tension. This transcription factor becomes activated as a result of a drop in the partial pressure of oxygen, to hypoxic levels below 5% oxygen, and targets a panel of genes involved in maintenance of oxygen homeostasis. Hypoxia is a common characteristic of the microenvironment of solid tumors and, through activation of the hypoxia-inducible factor, is at the center of the growth dynamics of tumor cells. Not only does the microenvironment impact on the hypoxia-inducible factor but this factor impacts on microenvironmental features, such as pH, nutrient availability, metabolism and the extracellular matrix. In this review we discuss the influence the tumor environment has on the hypoxia-inducible factor and outline the role of this factor as a modulator of the microenvironment and as a powerful actor in tumor remodeling. From a fundamental research point of view the hypoxia-inducible factor is at the center of a signaling pathway that must be deciphered to fully understand the dynamics of the tumor microenvironment. From a translational and pharmacological research point of view the hypoxia-inducible factor and its induced downstream gene products may provide information on patient prognosis and offer promising targets that open perspectives for novel “anti-microenvironment” directed therapies.

Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276PubMed

Padhani AR, Krohn KA, Lewis JS et al (2007) Imaging oxygenation of human tumours. Eur Radiol 17:861–872PubMed

Baish JW, Jain RK (2000) Fractals and cancer. Cancer Res 60:3683–3688PubMed

Grizzi F, Russo C, Colombo P et al (2005) Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer 5:14PubMed

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732PubMed

Hunter A, Hendrikse A, Renan M et al (2006) Does the tumor microenvironment influence radiation-induced apoptosis? Apoptosis 11:1727–1735PubMed

Brahimi-Horn MC, Pouyssegur J (2007) Harnessing the hypoxia-inducible factor in cancer and ischemic disease. Biochem Pharmacol 73:450–457PubMed

Mazure NM, Brahimi-Horn MC, Berta MA et al (2004) HIF-1: master and commander of the hypoxic world. A pharmacological approach to its regulation by siRNAs. Biochem Pharmacol 68:971–980PubMed

Manalo DJ, Rowan A, Lavoie T et al (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659–669PubMed

10.

Schofield CJ, Ratcliffe PJ (2004) Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5:343–354PubMed

11.

Lando D, Peet DJ, Gorman JJ et al (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466–1471PubMed

12.

Jaakkola P, Mole DR, Tian YM et al (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472PubMed

13.

Koivunen P, Tiainen P, Hyvarinen J et al (2007) An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. J Biol Chem 282:30544–30552PubMed

14.

Schofield CJ, Ratcliffe PJ (2005) Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 338:617–626PubMed

15.

Hewitson KS, McNeill LA, Riordan MV et al (2002) Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277:26351–26355PubMed

16.

Lee C, Kim SJ, Jeong DG et al (2003) Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J Biol Chem 278:7558–7563PubMed

17.

Bilton R, Trottier E, Pouyssegur J et al (2006) ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol 16:616–621PubMed

18.

Brahimi-Horn C, Mazure N, Pouyssegur J (2005) Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell Signal 17:1–9PubMed

19.

Hu CJ, Iyer S, Sataur A et al (2006) Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol Cell Biol 26:3514–3526PubMed

20.

Dayan F, Roux D, Brahimi-Horn MC et al (2006) The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res 66:3688–3698PubMed

21.

Koivunen P, Hirsila M, Gunzler V et al (2004) Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279:9899–9904PubMed

22.

Stolze IP, Tian YM, Appelhoff RJ et al (2004) Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J Biol Chem 279:42719–42725PubMed

23.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMed

24.

Gerhardt H, Golding M, Fruttiger M et al (2003) VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161:1163–1177PubMed

25.

Tang N, Wang L, Esko J et al (2004) Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 6:485–495PubMed

26.

Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55–60PubMed

27.

Noseda M, Chang L, McLean G et al (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24:8813–8822PubMed

28.

Seagroves TN, Ryan HE, Lu H et al (2001) Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol 21:3436–3444PubMed

29.

Mans AM, DeJoseph MR, Hawkins RA (1994) Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. J Neurochem 63:1829–1838PubMedCrossRef

30.

Hirsila M, Koivunen P, Xu L et al (2005) Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. Faseb J 19:1308–1310PubMed

31.

Vordermark D, Kraft P, Katzer A et al (2005) Glucose requirement for hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). Cancer Lett 230:122–133PubMed

32.

Natsuizaka M, Ozasa M, Darmanin S et al (2007) Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 313:3337–3348PubMed

33.

Shaw RJ, Kosmatka M, Bardeesy N et al (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101:3329–3335PubMed

34.

Bernardi R, Guernah I, Jin D et al (2006) PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442:779–785PubMed

35.

Laughner E, Taghavi P, Chiles K et al (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004PubMed

36.

Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014PubMed

37.

Lang KJ, Kappel A, Goodall GJ (2002) Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia. Mol Biol Cell 13:1792–1801PubMed

38.

Pore N, Jiang Z, Shu HK et al (2006) Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4:471–479PubMed

39.

Brugarolas J, Lei K, Hurley RL et al (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18:2893–2904PubMed

40.

Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7:961–967PubMed

41.

Lee H, Paik SG (2006) Regulation of BNIP3 in normal and cancer cells. Mol Cells 21:1–6PubMed

42.

Webster KA, Graham RM, Bishopric NH (2005) BNip3 and signal-specific programmed death in the heart. J Mol Cell Cardiol 38:35–45PubMed

43.

Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443PubMed

44.

Mazure NMBG, Garcia-Medina R, Gounon P, Roux D, Pouyssegur J (2007) Hypoxia-induced Autophagy is mediated through the HIF-dependent induction of BNIP3 and BNIP3L. Bull Cancer 94:534

45.

Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:425–434PubMed

46.

Kim JW, Tchernyshyov I, Semenza GL et al (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3:177–185PubMed

47.

Papandreou I, Cairns RA, Fontana L et al (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3:187–197PubMed

48.

Fukuda R, Zhang H, Kim JW et al (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129:111–122PubMed

49.

Tsukihara T, Aoyama H, Yamashita E et al (1996) The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 A. Science 272:1136–1144PubMed

50.

Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19:223–229PubMed

51.

Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899PubMed

52.

Mekhail K, Gunaratnam L, Bonicalzi ME et al (2004) HIF activation by pH-dependent nucleolar sequestration of VHL. Nat Cell Biol 6:642–647PubMed

53.

Willam C, Warnecke C, Schefold JC et al (2006) Inconsistent effects of acidosis on HIF-alpha protein and its target genes. Pflugers Arch 451:534–543PubMed

54.

Fukumura D, Xu L, Chen Y et al (2001) Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61:6020–6024PubMed

55.

Xu L, Fukumura D, Jain RK (2002) Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 277:11368–11374PubMed

56.

Kubasiak LA, Hernandez OM, Bishopric NH et al (2002) Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc Natl Acad Sci U S A 99:12825–12830PubMed

57.

Papandreou I, Krishna C, Kaper F et al (2005) Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 65:3171–3178PubMed

58.

Ullah MS, Davies AJ, Halestrap AP (2006) The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 281:9030–9037PubMed

59.

Shimoda LA, Fallon M, Pisarcik S et al (2006) HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol 291:L941–L949PubMed

60.

Cardone RA, Bellizzi A, Busco G et al (2007) The NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells. Mol Biol Cell 18:1768–1780PubMed

61.

Bergersen LH (2007) Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle. Neuroscience 145:11–19PubMed

62.

Koukourakis MI, Giatromanolaki A, Sivridis E et al (2005) Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 7:1–6PubMed

63.

Hosoya K, Kondo T, Tomi M et al (2001) MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res 18:1669–1676PubMed

64.

Hunt TK, Aslam RS, Beckert S et al (2007) Aerobically derived lactate stimulates revascularization and tissue repair via redox mechanisms. Antioxid Redox Signal 9:1115–1124PubMed

65.

Brahimi-Horn MC, Pouyssegur J (2007) Oxygen, a source of life and stress. FEBS Lett 581:3582–3591PubMed

66.

Fukuda R, Hirota K, Fan F et al (2002) Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277:38205–38211PubMed

67.

Zhong H, Chiles K, Feldser D et al (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545PubMed

68.

Richard DE, Berra E, Gothie E et al (1999) p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 274:32631–32637PubMed

69.

Sang N, Stiehl DP, Bohensky J et al (2003) MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278:14013–14019PubMed

70.

Mylonis I, Chachami G, Samiotaki M et al (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281:33095–33106PubMed

71.

Page EL, Robitaille GA, Pouyssegur J et al (2002) Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms. J Biol Chem 277:48403–48409PubMed

72.

Erler JT, Bennewith KL, Nicolau M et al (2006) Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440:1222–1226PubMed

73.

Lucero HA, Kagan HM (2006) Lysyl oxidase: an oxidative enzyme and effector of cell function. Cell Mol Life Sci 63:2304–2316PubMed

74.

Payne SL, Fogelgren B, Hess AR et al (2005) Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res 65:11429–11436PubMed

75.

Bouez C, Reynaud C, Noblesse E et al (2006) The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 12:1463–1469PubMed

76.

Ren C, Yang G, Timme TL et al (1998) Reduced lysyl oxidase messenger RNA levels in experimental and human prostate cancer. Cancer Res 58:1285–1290PubMed

77.

Petrella BL, Lohi J, Brinckerhoff CE (2005) Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 24:1043–1052PubMed

78.

Munoz-Najar UM, Neurath KM, Vumbaca F et al (2006) Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene 25:2379–2392PubMed

79.

Koike T, Kimura N, Miyazaki K et al (2004) Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A 101:8132–8137PubMed

80.

Esteban MA, Tran MG, Harten SK et al (2006) Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res 66:3567–3575PubMed

81.

Evans AJ, Russell RC, Roche O et al (2007) VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 27:157–169PubMed

82.

Krishnamachary B, Zagzag D, Nagasawa H et al (2006) Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66:2725–2731PubMed

83.

Funasaka T, Yanagawa T, Hogan V et al (2005) Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. Faseb J 19:1422–1430PubMed

84.

Pennacchietti S, Michieli P, Galluzzo M et al (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347–361PubMed

85.

Pan J, Mestas J, Burdick MD et al (2006) Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5:56PubMed

86.

Staller P, Sulitkova J, Lisztwan J et al (2003) Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307–311PubMed

87.

Fischer K, Hoffmann P, Voelkl S et al (2007) Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 109:3812–3819PubMed

88.

Lardner A (2001) The effects of extracellular pH on immune function. J Leukoc Biol 69:522–530PubMed

89.

Cramer T, Yamanishi Y, Clausen BE et al (2003) HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112:645–657PubMed

90.

De Palma M, Murdoch C, Venneri MA et al (2007) Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28:519–524PubMed

91.

Condeelis J, Pollard JW (2006) Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263–266PubMed

92.

Mantovani A, Schioppa T, Porta C et al (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25:315–322PubMed

93.

Hoekstra CJ, Stroobants SG, Smit EF et al (2005) Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23:8362–8370PubMed

94.

Daruwalla J, Christophi C (2006) The effect of hyperbaric oxygen therapy on tumour growth in a mouse model of colorectal cancer liver metastases. Eur J Cancer 42:3304–3311PubMed

95.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMed

96.

Beebe JS, Jani JP, Knauth E et al (2003) Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63:7301–7309PubMed

97.

Rugo HS, Herbst RS, Liu G et al (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474–5483PubMed

98.

Wedge SR, Ogilvie DJ, Dukes M et al (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655PubMed

99.

Peters KB, Brown JM (2002) Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62:5248–5253PubMed

100.

Le QT, Taira A, Budenz S et al (2006) Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer 106:1940–1949PubMed

101.

Smith HO, Jiang CS, Weiss GR et al (2006) Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer 16:298–305PubMed

102.

Groot AJ, Mengesha A, van der Wall E et al (2007) Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 364:985–989PubMed

103.

Magagnin MG, Koritzinsky M, Wouters BG (2006) Patterns of tumor oxygenation and their influence on the cellular hypoxic response and hypoxia-directed therapies. Drug Resist Updat 9:185–197PubMed

104.

Veschini L, Belloni D, Foglieni C et al (2007) Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 109:2565–2570PubMed

105.

Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122–127PubMed

106.

Lee K, Roth RA, LaPres JJ (2007) Hypoxia, drug therapy and toxicity. Pharmacol Ther 113:229–246

107.

Kong D, Park EJ, Stephen AG et al (2005) Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 65:9047–9055PubMed

108.

Mabjeesh NJ, Post DE, Willard MT et al (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62:2478–2482PubMed

109.

Epstein AC, Gleadle JM, McNeill LA et al (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107:43–54PubMed

110.

Pouyssegur J, Franchi A, Pages G (2001) pHi, aerobic glycolysis and vascular endothelial growth factor in tumour growth. Novartis Found Symp 240:186–196 discussion 196–188PubMed

Title: A Dialogue between the Hypoxia-Inducible Factor and the Tumor Microenvironment
Authors: Frédéric Dayan
Nathalie M. Mazure
M. Christiane Brahimi-Horn
Jacques Pouysségur
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Cancer Microenvironment / Issue 1/2008
Print ISSN: 1875-2292
Electronic ISSN: 1875-2284
DOI: https://doi.org/10.1007/s12307-008-0006-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Neuroblastoma Cell Death is Induced by Inorganic Arsenic Trioxide (As2O3) and Inhibited by a Normal Human Bone Marrow Cell-Derived Factor

Metastasis Suppressors and the Tumor Microenvironment

Role of Cancer Microenvironment in Metastasis: Focus on Colon Cancer

Microenvironment Changes (in pH) Affect VEGF Alternative Splicing

Systems Biology: A Therapeutic Target for Tumor Therapy

Significance of Toll-like Receptors Expression in Tumor Growth and Spreading: A Short Review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer